

410



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/24		A1	(11) International Publication Number: WO 98/03638 (43) International Publication Date: 29 January 1998 (29.01.98)
(21) International Application Number: PCT/AU97/00452 (22) International Filing Date: 18 July 1997 (18.07.97) (30) Priority Data: PO 1113 18 July 1996 (18.07.96) AU PO 3323 30 October 1996 (30.10.96) AU (71) Applicant (for all designated States except US): THE AUSTRALIAN NATIONAL UNIVERSITY [AU/AU]; Acton, ACT 2601 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): FREEMAN, Craig, Geoffrey [AU/AU]; 31 Woollum Place, Rivett, ACT 2611 (AU). PARISH, Christopher, Richard [AU/AU]; 62 Vasey Crescent, Campbell, ACT 2601 (AU). (74) Agents: SLATTERY, John, Michael et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: DETECTION OF MAMMALIAN HEPARANASE ACTIVITY AND PURIFICATION OF MAMMALIAN HEPARANASE			
(57) Abstract A method for detecting mammalian heparanase activity in a sample such as mammalian tissue, cells or bodily fluids; and a method for the purification of mammalian heparanase from a heparanase-containing material, such as human platelets.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

DETECTION OF MAMMALIAN HEPARANASE ACTIVITY AND PURIFICATION OF MAMMALIAN HEPARANASE

FIELD OF INVENTION

5

This invention relates to an assay for the detection of mammalian heparanase activity present in a variety of mammalian tissues, cells and bodily fluids, including serum and both normal and cancerous cells and tissues, and which may be used for the determination of mammalian heparanase activity from a variety of tissue and cell sources,
10 as a diagnostic tool for the determination of metastatic potential, and for the development of specific inhibitors of heparanase activity and metastasis.

The invention also relates to a method for the purification of mammalian heparanase, in particular human platelet heparanase, and to the purified mammalian
15 heparanase obtainable by this method. The availability of purified mammalian heparanase such as human platelet heparanase will facilitate the development of inhibitors of mammalian heparanase activity, the production of monoclonal antibodies against the enzyme, and the identification of amino acid and cDNA sequence of the enzyme for the ultimate cloning and the expression of the enzyme.

20

BACKGROUND OF THE INVENTION

Important processes in tissue invasion by blood-borne malignant tumour cells and leukocytes include their adhesion to the luminal surface of the vascular endothelium,
25 their passage through the vascular endothelial cell layer and the subsequent degradation of the underlying basal lamina and extracellular matrix (ECM) with a battery of secreted and/or cell surface protease and glycosidase activities (Nakajima et al, 1983; Schmitt et al, 1992; Vlodavsky et al, 1992). The basal lamina and underlying connective tissue stroma consist predominantly of a complex network of fibronectin, laminin, collagen type
30 IV and vitronectin, each of which interact with heparan sulphate (HS) side chains of

- 2 -

heparan sulphate proteoglycans (HSPG) embedded within the matrix (Yurichenco and Schittny, 1990). HS chains generally consist of clusters of sulphated disaccharide units (predominately N-sulphated glucosamine linked 1-4 to α -L-iduronic acid residues) separated by lowly or non-sulphated regions (predominately disaccharide units of N-acetylated glucosamine linked 1-4 to β -D-glucuronic acid) (Turnbull and Gallagher, 1990,1991). Cleavage of the HS chains by endoglycosidase or heparanase activity produced by invading cells may therefore assist in the disassembly of the ECM and facilitate cell migration. Heparanase activity has been shown to be related to the metastatic potential of murine and human fibrosarcoma and melanoma cell lines (Nakajima et al, 1983, 1986a,b, 1988; Ricoveri and Cappelletti, 1986). Furthermore, heparanase activity has been described in a number of tissues and cell types including rat liver (Gallagher et al, 1988; Hook et al, 1975), human placenta (Klein and Von Figura, 1979; Lider et al, 1989), human platelets (Hoogewerf et al, 1995; Oldberg et al, 1980; Oosta et al, 1982), cultured human skin fibroblasts (Klein and Von Figura, 1976), human neutrophils (Matzner et al, 1985, 1992), activated but not resting rat T-lymphocytes (Naparstek et al, 1984), normal and neoplastic murine B-lymphocytes (Laskov et al, 1991), human monocytes (Sewell et al, 1989) and human umbilical vein endothelial cells (Bartlett et al, 1995; Godder et al, 1991). Because the cleavage of HS appears to be essential for the passage of metastatic tumour cells and leukocytes through basement membranes, studies of heparanase inhibitors provide the potential of developing novel and highly selective classes of anti-metastatic and anti-inflammatory drugs (Coombe et al, 1987; Irimura et al, 1986; Parish et al, 1990; Vlodavsky et al, 1992; Willenborg and Parish 1988).

25 The expression of heparanase activity by platelets, metastatic tumour cells and circulating cells of the immune system has been related to their involvement in their diapedes and extravasation. Studies have shown that while the initial entrapment of metastatic tumour cells by the capillary endothelium is platelet-independent, platelet aggregation which occurs shortly afterwards can lead to platelet activation and
30 degranulation, resulting in gap formation and retraction of endothelial cells exposing the

- 3 -

underlying basement membrane to adhesion by the tumour cells (Tanaka et al, 1986; Crissman et al, 1985; Yahalom et al, 1985). Human platelets have been shown to contain high levels of heparanase activity, capable of degrading endothelial cell surface, tumour-derived and ECM-derived HSPG (Bartlett et al, 1995a, 1995b; Castellot et al, 1982; 5 Hoogewerf et al, 1995; Wasteson et al, 1976, 1977; Yahalom et al, 1984;) as well as free HS and heparin chains (Graham et al, 1995a and b; Oldberg et al, 1980; Oosta et al, 1982; Wasteson et al, 1976, 1977). To date, three separate mammalian cell heparanase activities have been reported: mouse melanoma B16 heparanase which cleaves HS only, human platelet heparanase which cleaves both heparin and HS and a mouse mastocytoma 10 endoglucuronidase which was reported to cleave newly synthesised heparin precursor but not heparin or HS (Hoogewerf et al 1995; Nakajima et al, 1988; Thunberg et al, 1982). More recent studies have indicated that murine melanoma and macrophage extracts are in fact able to degrade both HS and heparin, however heparin was degraded to a lesser extent than by human platelet extracts (Graham and Underwood, 1996). Although 15 Hennes et al (1988) reported that tumour-derived heparanase was able to degrade matrix HS but was unable to degrade endothelial cell surface HS, human platelets have been shown to degrade endothelial cell surface HS (Wasteson et al, 1977) which was shown by Gamse et al (1978) to be more heparin-like in structure. Thus, it is likely that the platelet heparanase, which is capable of degrading both heparin and HS, may play a 20 critical role in degrading cell-surface HS in focal adhesion plaques, and aiding the extravasation of blood-borne cells.

Following partial purification of human platelet heparanase by Oldberg et al (1980), who determined that the enzyme was an endoglucuronidase which acted upon 25 N-sulphated, iduronic acid-containing heparin biosynthetic intermediates, the enzyme was purified 240,000-fold to apparent homogeneity in 6% yield by a 6-column procedure (Oosta et al, 1982). The enzyme was a 134 kDa single subunit protein which was active towards ¹²⁵I-heparin and was confirmed to be an endoglucuronidase. In subsequent studies, the platelet heparanase was shown to cleave endothelial cell surface heparin-like 30 material which inhibited smooth muscle cell proliferation (Castellot et al, 1982) and to

- 4 -

cleave the antithrombin III (AT III)-binding octasaccharide between GlcA-GlcNS3S (Thunberg et al, 1982), presumably resulting in the loss of the anticoagulant activity of heparin following its degradation (Oldberg et al, 1980). Although, the purified enzyme was shown to act towards an octasaccharide substrate, platelet extracts were also shown to degrade ECM-derived HS chains to 10 kDa (Yahalom, et al 1984) and to 5 kDa fragments (Freeman and Bartlett, unpublished observations), indicating the existence of specific structural motifs determining the site of cleavage. The size of heparin-cleavage products following platelet heparanase action has not been determined (Graham and Underwood, 1996; Oldberg et al, 1980; Oosta et al, 1982). Recently, however, Hoogewerf et al (1995) reported the 4100-fold purification of a human platelet heparanase activity in 8% yield which was shown to be an endoglucosaminidase that cleaved both heparin and HS principally to disaccharides following radiolabelling of the digestion products. The activity resided in the 8-10 kDa subunit CXC chemokines connective tissue activating peptide-III (CTAP-III) and neutrophil activating peptide-2 (NAP-2) which are members of the platelet basic protein family. In contrast, Graham and Underwood (1996) has since shown that the heparanase activity in human platelet extracts had a Mr of 40-60 kDa, and cleaved both HS and heparin, although the size of the degradation products was not determined.

20 The resolution of the reported differences in the molecular size (8 to 134kDa), the substrate specificity (whether the enzyme is an endo-glucuronidase or endo-glucosaminidase activity), and the size of the substrate cleavage products (disaccharides or 5 to 10kDa) requires purification of the enzyme(s) to homogeneity in high yield. While some studies of the substrate specificity of the platelet enzyme have been reported (Oldberg, et al 1980; Oosta et al, 1882; Thunberg, et al 1982), surprisingly little has been reported on the inhibition of the enzyme by sulphated polysaccharides (similar to the studies by Nakajima et al (1986a and b)) on the inhibition of tumour cell heparanase activity) apart from the use of some modified heparins and heparin itself to inhibit platelet degradation of ECM-associated HSPG (Eldor, et al 1987). This is especially surprising

- 5 -

considering the potentially important role of platelets during the initial stages of tumour cell extravasation.

In order to purify and characterise mammalian heparanase activities and to screen
5 for and develop effective heparanase inhibitors, a simple and rapid assay for heparanase activity is required. However, previous heparanase assays have been cumbersome and time consuming in both preparation of radiolabelled substrate and separation of degradative products from the uncleaved substrate. Frequently heparanase assays have involved the biosynthetic radio-labelling of ECM-associated HSPG and the detection of
10 HS chain degradation by gel filtration analysis of radiolabelled material released from the ECM (Bartlett et al, 1995; Vlodavsky et al, 1992 and references within). Such an approach suffers from the main disadvantage that degradation of HS chains in an ECM involves the synergistic action of proteases which are required to expose the HS chains for subsequent heparanase attack (Bar-Ner et al, 1985, 1986; Benezra et al, 1992; Vlodavsky et al, 1988).
15 Furthermore, most heparanase assays have required extensive degradation of the radiolabelled HS (or ECM-derived HSPG) substrate to allow separation of the degraded product from the substrate by gel filtration (Bartlett et al, 1995; Klein and Von Figura, 1979; Nakajima et al, 1986a; Vlodavsky et al, 1992), although cleavage of HS chains at a single site may be all that is required to allow passage of leukocytes and tumour cells
20 through the basement membrane. Solid phase heparanase assays also have been developed where chemically and biosynthetically radiolabelled heparin and HS chains were attached to a solid support with release of radiolabel from the solid support being a measure of enzyme activity (Nakajima et al, 1986a; Oosta et al, 1982; Sewell et al, 1989). Such assays, however, suffer from the disadvantage that the immobilized substrate
25 may be less accessible to the mammalian heparanase enzyme, and the coupling of the radiolabelled substrate to the solid support, via the substrate's reducing terminus, is a complex and inefficient procedure. Previous studies have also radiolabelled both heparin and HS by iodination at naturally occurring glucosamine residues (Oosta et al, 1982) or by N-acetylation of the partially de-N-sulphated substrate (Nakajima et al, 1986a). Such

- 6 -

procedures, however, may result in the masking, or the creation of new heparanase cleavage sites.

SUMMARY OF THE INVENTION

5

In one aspect, the present invention provides a method for detecting mammalian heparanase activity in a sample such as mammalian tissue, cells or bodily fluids.

In accordance with this aspect, the present invention provides a method for the
10 detection of mammalian heparanase activity in a sample, which comprises the steps of:

- (i) contacting the sample to be tested with a heparanase substrate for a time and under conditions sufficient for heparanase in the sample to degrade the heparanase substrate;
- (ii) separating degradation products from undegraded or partially degraded
15 heparanase substrate by binding the undegraded or partially degraded heparanase substrate with a heparan sulphate-binding protein; and
- (iii) detecting separated degradation products to indicate heparanase activity in the sample.

20 In this aspect, the present invention also provides a kit for use in the detection of mammalian heparanase activity in a sample, which comprises, in compartmentalized form:

- (i) heparanase substrate;
- (ii) heparan sulphate-binding protein; and
- 25 (iii) optionally, directions for performing the method of the invention as broadly described above.

In another aspect, the present invention provides a novel procedure for the rapid purification of mammalian heparanase activity, more particularly human platelet

- 7 -

heparanase activity, as well as purified mammalian heparanase prepared by this procedure.

According to this aspect, the present invention provides a method for the purification of mammalian heparanase from a heparanase-containing material, which
5 comprises the steps of:

- (i) contacting the heparanase-containing material with an immobilised lectin affinity chromatography matrix in the presence of detergent to bind heparanase activity to said matrix;
- 10 (ii) eluting a first purified heparanase-containing fraction from said matrix;
- (iii) optionally contacting said first purified heparanase-containing fraction with an immobilised metal ion affinity chromatography matrix;
- 15 (iv) contacting said first purified heparanase-containing fraction with a dye-resin matrix to bind heparanase activity to said dye-resin matrix; and
- (v) eluting a second purified heparanase-containing fraction from said dye-resin matrix.

20

In this aspect, the present invention also provides substantially purified mammalian heparanase prepared by the method described broadly above, in particular substantially purified human platelet heparanase characterised in that it has a native molecular mass (Mr) of about 50kDa when analysed by gel filtration chromatography and by SDS-PAGE,
25 and in that it degrades both heparin and heparan sulphate. The substantially purified human platelet heparanase of this invention degrades bovine lung and porcine mucosal heparin from 12kDa to 6 and 4kDa fragments respectively, and porcine mucosal heparan sulphate in a stepwise fashion from 22kDa to 5kDa fragments, by gel filtration analysis.

- 8 -

The heparanase purification method of this invention as broadly described above may also be used to purify other heparanases, including rat liver, rat 13762 MAT adenocarcinoma cell and human HCT116 colonic carcinoma cell heparanase. Substantially purified MAT and HCT cell heparanase have similar Mr to the human
5 platelet heparanase discussed above, while substantially purified rat liver heparanase has a native Mr of about 45kDa and has 3 bands on SDS-PAGE between 43 and 47kDa.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to
10 imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

DETAILED DESCRIPTION OF THE INVENTION

15 In one aspect, the present invention relates in particular to the detection of mammalian heparanase activity in serum, including serum of human cancer patients, as well as in a variety of tissue and cell homogenates or extracts, including for example human platelets, colonic carcinoma cells, umbilical vein endothelial cells and rat mammary adenocarcinoma cells (both metastatic and non-metastatic variants) and liver
20 homogenates. The method may be used to determine heparanase activity in both human and non-human (e.g. rat and murine) sera, cell and tissue homogenates or extracts.

Preferably, the heparanase substrate is a labelled substrate, more preferably a radiolabelled substrate. The substrate is preferably heparan sulphate (HS) and particularly
25 preferred substrates are ³H-porcine mucosal HS and ³H-bovine kidney HS. Preferably, porcine mucosal HS is partially de-N-acetylated and re-N-acetylated with ³H-acetic anhydride to yield the desired radiolabelled substrate.

As broadly described above, the sample to be tested is contacted with the
30 heparanase substrate for a time and under conditions sufficient for heparanase, if any, in

- 9 -

the sample to degrade the substrate. Suitable incubation times and conditions can be readily determined without undue experimentation. By way of example, incubation of the sample with the substrate may be carried out at a temperature in the range of 35°C to 40°C, preferably about 37°C, for a period of from 2 to 48 hrs, preferably about 16 hrs, at a pH in the range of from 4.2 to 7.5, preferably about pH 5.1. Preferably, the incubation step is performed in the presence of bovine serum albumin, N-acetylmannosamine and/or a detergent such as Triton X-100. As described in detail below, heparanase activity under suitable incubation times and conditions degrades the preferred porcine mucosal heparan sulphate substrate in a stepwise fashion from 22 to 17, then to 8 and finally to 5 kDa fragments or degradation products.

Separation of degradation products from undegraded or partially degraded heparanase substrate is carried out by binding to a heparan sulphate-binding protein. As used herein, the term "heparan sulphate-binding protein" includes, but is not limited to heparin-binding proteins. A particularly preferred heparan sulphate-binding protein for use in the present invention is histidine-rich glycoprotein. More preferably, the histidine-rich glycoprotein (HRG) is chicken HRG, however other HRG including human HRG may also be used. It is to be understood, however, that the present invention extends to the use of other heparan sulphate- and heparin-binding proteins other than HRG including, for example, protease inhibitors such as antithrombin 111 and heparin cofactor 11; plasma lipoproteins such as apolipoprotein B-100 and apolipoprotein E; growth factors such as acidic and basic fibroblast growth factor, vascular endothelial growth factor, hepatocyte growth factor and platelet-derived growth factor; extracellular matrix proteins such as laminin, collagen and elastin; enzymes such as lipoprotein lyase, superoxide dimutase, cathepsin G, elastase and the bacterial heparin lyases 1, 11 and 111; and other suitable binding proteins such as platelet factor 4, von willebrand factor, and β -thromboglobulin. The present invention also extends to peptides derived from these heparan sulphate- or heparin-binding proteins particularly HRG, which contain the heparan sulphate- or haparin-binding region.

- 10 -

Preferably, the separation is carried out by binding to an immobilised heparan sulphate-binding protein. Any suitable method of immobilisation may be used, however it is presently preferred to immobilise HRG or other suitable binding protein by binding to agarose, more particularly Sepharose, beads. In this preferred aspect, the HRG-
5 Sepharose beads may be loaded in a column, and the incubation mixture applied to and washed through the column to bind undegraded or partially degraded heparanase substrate, with degradation products being unbound or bound less efficiently to the HRG-Sepharose beads. Alternatively, the HRG or other suitable binding protein may be added to an incubation mixture to bind to undegraded or partially degraded heparanase substrate
10 complex, and the complex may then be separated, for example by immobilisation on a substrate (such as Immobilon or StrataClean) leaving degraded heparanase substrate fragments in the incubation mixture following removal of the immobilised complex, for example by centrifugation or filtration.

15 In the final step of the method of this aspect of the invention, separated degradation products are detected to indicate the presence of heparanase activity in the sample under test. This detection step may include quantitative and/or qualitative detection of the degradation products. Where a radiolabelled heparanase substrate such as a ^3H -porcine mucosal HS is used, the detection step may consist of detection of
20 radioactivity levels of unbound degradation products.

The present invention provides in this aspect a novel method for separating degradation products from the heparanase substrate by taking advantage of the decreased affinity of the cleaved heparanase degradation products for a heparan sulphate-binding
25 protein such as HRG, particularly chicken histidine-rich glycoprotein (cHRG). Incubation mixtures are applied to cHRG-Sepharose columns, with unbound material corresponding to heparanase degradation products. Heparanase activity has been determined for a variety of human, rat and murine cell and tissue homogenates. By way of example, highly metastatic rat mammary adenocarcinoma and murine melanoma cell lines had 4 to 10
30 times the heparanase activity compared to non-metastatic variants, confirming the

- 11 -

correlation of heparanase activity with metastatic potential. Human cancer patients had twice the serum heparanase levels as normal healthy adults.

This aspect of the present invention provides a new, simple and rapid quantitative
5 assay for the detection of mammalian heparanase activity towards a natural radiolabelled substrate which can detect the minimal number of HS chain cleavages which are likely to occur *in vivo*, and which is based upon a novel principle, namely the loss of a protein binding site on HS chains following chain cleavage. In the assay, advantage is taken of an initial observation that the HS-binding plasma protein HRC masks heparanase cleavage
10 sites on HS chains. Following heparanase digestion, radiolabelled HS fragments (products) are not bound by mini-columns of HRC-coupled Sepharose beads unlike the remaining intact and partially degraded substrate, allowing a rapid separation of the cleaved product from the substrate.

15 The assay of this aspect of the invention has several advantages over conventional assays in (a) ease of preparation of relatively large quantities of a radiolabelled natural substrate while maintaining the native structure, (b) allowing the rapid and simultaneous determination of a large number of samples and (c) allowing accurate quantification of heparanase activity by detecting single site cleavage of the substrate.

20

In another aspect, the present invention relates to the purification of mammalian heparanase from heparanase-containing material. The heparanase-containing material which is used as a starting material in the method of the present invention may be any source of mammalian heparanase activity, for example human colonic carcinoma HCT
25 116 cells, rat mammary adenocarcinoma 13762 MAT cells, or rat liver tissue. The present invention is, however, particularly directed to purification of human platelet heparanase, and a convenient source of this material is obtained by solubilisation of enzyme activity from a homogenate of frozen, washed human platelets.

- 12 -

The heparanase-containing material is subjected to immobilised lectin affinity chromatography, preferably concanavalin A-Sepharose chromatography, in the presence of detergent (such as Triton X-100) to bind the heparanase activity to the chromatography column. Elution of the bound heparanase activity provides a first purified heparanase-
5 containing fraction.

Optionally, and preferably, the first purified heparanase-containing fraction is then subjected to immobilised metal ion affinity chromatography (IMAC), preferably using a matrix such as Zn^{2+} -chelating Sepharose, which does not bind the heparanase activity but
10 which removes other contaminating proteins. The first purified heparanase-containing fraction is then subjected to dye-resin chromatography, preferably in series with the IMAC matrix, to again bind the heparanase activity. Suitable dye-resin matrixes include a Blue-A agarose matrix, although other dyes such as Reactive Red may also be used as well as other matrix supports such as Sepharose and acrylamide. Elution of a second purified
15 heparanase-containing fraction from the dye-resin matrix may be followed by octyl-agarose chromatography which again binds contaminating proteins without binding the heparanase activity.

Final purification of the second purified heparanase-containing fraction may be
20 carried out by gel filtration chromatography, for example Superose 12 chromatography, optionally followed by concentration of the purified enzyme.

As previously described the product obtained in accordance with this aspect of the present invention is substantially purified mammalian heparanase, in particular
25 substantially purified human platelet heparanase. The term "substantially purified" as used in the present specification denotes that the product has been subjected to purification procedures such that the heparanase enzyme activity is at least 1000-fold, preferably at least 1,500-fold when compared with the activity of the heparanase-containing starting material.

- 13 -

Preferably also, the substantially purified mammalian heparanase is homogeneous, and preferably contains at least 75% by weight, even more preferably at least 85% by weight, and most preferably at least 95-99% by weight of the heparanase enzyme, relative to other proteins with which it is normally associated in its native form.

5

In accordance with this aspect of the present invention, human platelet heparanase has been purified to homogeneity from previously frozen, washed platelets. Human platelets have been shown to contain very high amounts of heparanase activity compared to metastatic tumour cells and other cell types when expressed as activity/mg of protein.

10

In one embodiment of this aspect of the method of this invention which is described in detail in the Example below, human platelet heparanase has been purified 1900-fold to homogeneity in 19% yield by a five column procedure, which consists of concanavalin A-Sepharose, Zn^{2+} -chelating-Sepharose, Blue A-agarose, octyl-agarose and
15 gel filtration chromatography. The same purification procedure can be used to purify other mammalian heparanase activities, eg from human colonic carcinoma HCT 116 cells, rat mammary adenocarcinoma 13762 MAT cells and from rat liver. The human platelet heparanase, which degrades both heparin and HS, had a native molecular mass of 50kDa when analysed by gel filtration chromatography and by SDS-PAGE. The enzyme
20 degraded porcine mucosal HS in a stepwise fashion from 22 to 17, 10 and finally to 5kDa fragments while bovine lung and porcine mucosal heparin were degraded from 12 kDa to 6 and 4 kDa fragments respectively by gel filtration analysis.

Further details of the present invention will be apparent from the detailed
25 description in the following Example which is included by way of illustration and not limitation of the invention, and the accompanying drawings.

In the drawings:

Figure 1: Degradation of HS as a function of incubation pH. HS was
30 incubated with rat 13762 MAT homogenate at pH 4.2 (O), 5.1 (□), 6.5 (Δ) and 7.5 (▲)

- 14 -

and in the absence of added enzyme at pH 5.1 (■) for 16h at 37°C. The incubation mixtures were fractionated by Superose-6 gel filtration chromatography. Mr standards shown are a) 16.7, b) 10.6, c) 6.7, d) 3.1 and e) 0.2 kDa. For full details, see the Methods section.

5

Figure 2: Degradation of HS as a function of incubation time. HS was incubated with rat 13762 MAT homogenate at pH 5.1 for 2 (Δ), 4 (▲) and 16 hr (□) and in the absence of added enzyme for 4 hr (■) at 37°C. The incubation mixtures were fractionated by Superose 6 gel filtration chromatography. Mr standards a-e are as described in Fig. 1. For full details, see the Methods section.

Figure 3: Degradation of HS by homogenates of metastatic and non-metastatic rat mammary adenocarcinoma cell lines. HS was incubated at pH 5.1 for 16h at 37°C with no enzyme (■), homogenates of the non-metastatic variants DMBA-Sask (□) and 13762 MAT (J-clone) (▲) and the highly metastatic 13762 MAT and DMBA-8A cell lines (Δ) shown together for convenience. The incubation mixtures were fractionated by Superose 6 gel filtration chromatography. Mr standards a-e are as described in Fig. 1. For full details, see the Methods section.

Figure 4: Degradation of HS as a function of incubation time and affinity of the digested HS products for cHRG-Sepharose. HS was incubated at pH 5.1 for 2 (□), 4 (Δ) and 16hr (▲) and in the absence of added enzyme for 4hr (■) at 37°C. The incubation mixtures were applied to a cHRG-Sepharose column in PBS, washed with PBS and eluted by a NaCl-gradient. The arrow indicates the start of the NaCl gradient. —, Concentration of NaCl. For full details, see the Methods section.

Figure 5: Inhibition of HS degradation by cHRG. HS was incubated at pH 5.1 for 8h at 37°C in the absence of added enzyme or cHRG (■) and with rat 13762 MAT cell homogenate in the presence (Δ) and absence (▲) of a 3:1 (cHRG:HS) molar ratio of

- 15 -

cHRG. The incubation mixtures were fractionated by Superose 6 gel filtration chromatography. Mr standards a-e are as described in Fig 1. For full details, see the Methods section.

5 **Figure 6:** Degradation of HS as a function of incubation time. HS was incubated with rat 13762 MAT homogenate at pH 5.1 for 2 (□), 4 (▲), 6 (△), 8 (●) and 10 hr (○) and in the absence of added enzyme for 4hr (■) at 37°C. The incubation mixtures were divided and fractionated by A) Sepharose 6 gel filtration chromatography and B) binding to a cHRG-Sepharose column where the unbound fraction was determined for 10 each time point. Mr standards a-e are as described in Fig. 1. For full details, see the Methods section.

Figure 7: Superose 12 chromatography of human platelet heparanase. Platelet heparanase from Step 4 was purified by gel filtration as described in the Method section. 15 Fractions were assayed for heparanase activity (○) and monitored for protein (—A280). Arrows 1 and 2 indicate V_e for bovine serum albumin and ovalbumin respectively.

Figure 8: SDS-PAGE of purified human platelet heparanase. Step 5 purified platelet heparanase was reduced with dithioerythritol and electrophoresed in a 10% 20 polyacrylamide gel. For experimental details, see the Methods section. Lane 1, Mr standards; lane 2, Step 5 heparanase.

EXAMPLE 1

25 Abbreviations used: bFGF, basic fibroblast growth factor; BSA, bovine serum albumin; cHRG, chicken histidine-rich glycoprotein; CNBr, cyanogen bromide; CR-HS, carboxyl-reduced heparan sulphate; ECM, extracellular matrix; GlcA, glucuronic acid; GlcNAc, N-acetylated glucosamine; GlcNS, N-sulphated glucosamine; GlcNS3S, glucosamine N,3-disulphate; hHRG, human histidine-rich glycoprotein; HRG, 30 histidine-rich glycoprotein; HS, heparan sulphate; HSPG, heparan sulfate proteoglycan;

- 16 -

HUVEC, human umbilical vein endothelial cells; IdoA2S, iduronic acid 2-sulphate; NAM, N-acetylmannosamine; PBS, phosphate buffered saline.

I - MATERIALS

5

Heparin-derived molecular mass ($M_{r_{ave}}$) standards of 16.7, 10.6, 6.7 and 3.1 kDa were a generous gift from Nova Nordisk (Gentofte, Denmark) (see Kristensen et al, 1991). Porcine mucosal HS (ORG 553) was a generous gift from Organon Int. Bv, (Oss, The Netherlands). Pharmacia Fine Chemicals (Uppsala, Sweden) supplied PD-10 columns, 10 DEAE-Sepharose and cyanogen bromide activated-Sepharose 4B. Sigma Chemical Co. (St Louis, MO) supplied crystalline bovine serum albumin, bovine lung heparin, chondroitin ABC-lyase, hydrazine hydrate and hydrazine sulphate. ^3H -Acetic anhydride (500mCi/mmol) in toluene solution was obtained from Amersham International (Sydney, Australia). Beckmann (Gladesville, Australia) supplied Ready Safe scintillation fluid. 15 Dowex AG50W-X8 (100-200 mesh; H⁺ form) was obtained from Bio-Rad Laboratories (Richmond, CA).

The following cell lines were cultured and harvested as previously described: the metastatic human colonic carcinomas HCT 116 (Schlechte et al, 1989) and KM 12 SM 20 (Morikawa et al, 1988); the metastatic murine melanoma B16-F10, the highly metastatic 13762 MAT and DMBA-8A rat mammary adenocarcinoma, and their non-metastatic variants J-clone and DMBA-Sask (Parish et al, 1992); human umbilical vein endothelial cells and the macrophage cell line U937 (Bartlett et al, 1995); human smooth muscle, human lung fibroblasts and human keratinocyte cell line (KJD). Human platelets were 25 obtained by the method of Bartlett et al, (1995). The murine Lewis lung carcinoma (metastatic (D122) and non-metastatic (LLC) variant) and the murine lung carcinoma cell lines (metastatic (A3a) and non-metastatic (SP1) variant) were generous gifts from Dr. James W. Dennis, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada and Dr. Lea Eisenbach, Department of Immunology, The Weizmann Institute of 30 Science, Rehovot, Israel respectively. Cell pellets from these cell lines were supplied

- 17 -

frozen (-80°C) by Dr Robin Anderson, Peter MacCallum Cancer Institute, Melbourne, Australia. Cell homogenates were prepared by suspending 10^6 cells or 10^8 platelets (which had been previously washed in normal saline) in 0.2ml of 0.1% (v:v) aqueous Triton X-100 and disrupting by freezing and thawing three times in a solid-CO₂/ethanol mixture.

Freshly excised livers from 10 week old Fischer F344 rats were homogenised in 3 volumes (w:v) of 15mM-dimethylglutarate buffer, pH 6.0, containing 0.5M-NaCl using a polytron homogeniser. Serum and both tumorigenic and adjacent normal lung tissue from human cancer patients was obtained frozen (-80°C) from the Royal North Shore Hospital, Sydney, Australia. The tissue was thawed and homogenised as described above. Frozen serum from cancer patients and healthy volunteers was thawed and dialysed for 16h at 4°C against normal saline. Protein concentrations were estimated by a Bio-Rad Coomassie protein assay kit (Bio-Rad Laboratories, Richmond, CA) using BSA as a standard.

II - METHODS

Radiolabelled heparan sulphate: Crude porcine intestinal mucosal heparan sulphate ORG553 (100mg) was dissolved in 2ml H₂O, dialysed for 4h against 2l of normal saline and for 16h against 2l H₂O at 4°C in dialysis tubing with a 10 kDa cut-off. The dialysed solution was mixed with 2ml of 0.1M-Tris.HCl, pH 8.0, containing 0.1mg/ml BSA and 2 units of chondroitin ABC-lyase, and incubated at 37°C for 16h. Following dialysis at 4°C for 16h against 2l PBS, the solution was applied to a DEAE-Sepharose column (1.0 x 6.0cm) equilibrated in PBS. The column was washed successively with 12ml each of PBS and 0.3M-NaCl before being eluted with 10ml of 2M-NaCl which was subsequently lyophilized. The solid was dissolved in the minimum amount of H₂O, and desalted using a Pharmacia PD-10 column. The eluant appearing ahead of the NaCl (detected by addition of a drop of a 20% silver nitrate solution) was lyophilized to yield 33mg of purified heparan sulphate.

- 18 -

The purified heparan sulphate (26mg) was dissolved in hydrazine hydrate (1ml) containing hydrazine sulphate (20mg) and the mixture heated at 100°C for 2h in a capped glass vial. The mixture was cooled and dried under a stream of nitrogen. Toluene (1 ml) was added, the mixture dried and this procedure repeated twice more. The residue was dissolved in 2ml of 1M-NaCl, desalted on a PD-10 column and the desalted material passed through a Dowex 50X-8 (Na⁺ form) column (1.0 x 6.0cm) which was washed with a further 10ml H₂O. The combined flow through and washings were lyophilized to yield 19mg of partially de-N-acetylated heparan sulphate.

10 The de-N-acetylated heparan sulphate (19mg) was dissolved in 1ml of 0.5M-NaHCO₃, containing 10% (v:v) methanol, cooled to 0°C in an ice bath and 0.1ml of ³H-acetic anhydride (5mCi, 500mCi/mmol) in toluene added, and the mixture stirred vigorously for 3h at 0°C. A further 0.05ml methanol, 0.1 ml Na₂CO₃ and 0.05ml acetic anhydride were added with stirring for 30 min at 0°C. This procedure was repeated twice
15 more, checking the pH remained alkaline before the mixture was acidified to pH4.0 with acetic acid. After the mixture was warmed to 22°C, the toluene was removed under a stream of nitrogen and the solution desalted on a PD-10 column equilibrated and developed in 10% (v:v) aqueous ethanol. Radioactive material appearing ahead of the ³H-acetate peak was lyophilized to yield 21 mg of radiolabelled heparan sulphate which
20 was dissolved in 10% (v:v) aqueous ethanol at a concentration of 2mg/ml and stored at -20°C.

Histidine-rich glycoprotein-Sepharose: Chicken histidine-rich glycoprotein (cHRG) was prepared from chicken plasma by phosphocellulose ion exchange chromatography
25 (Rylatt et al, 1981). The purity of the preparation was demonstrated by SDS-PAGE where a single Coomassie Blue stained band with a molecular mass of 135kDa was detected. The material was concentrated to a protein concentration of 2mg/ml, dialysed against PBS and stored at -20°C until use.

- 19 -

Bovine lung heparin (50mg) was dissolved in 10ml of 0.5M-NaHCO₃ containing 10% (v:v) methanol and cooled to 4°C before 5 aliquots of 0.04ml acetic anhydride was added at 5 min intervals. The pH was kept above 8.0 with 1M-Na₂CO₃. The mixture was stirred for a further 30 min before the acetylated heparin was dialyzed for 16h at 4°C against 5l of 1M-NaHCO₃ containing 0.15M-NaCl (coupling buffer).

cHRG (10mg) was dialysed for 16h at 4°C against 2l of coupling buffer and mixed at 4°C for 30 min with the acetylated heparin solution prepared above to prevent coupling of the HS-binding site of cHRG to the Sepharose beads. Cyanogen bromide (CNBr)-activated Sepharose 4B (2g) was swollen in 50ml of 1mM-HCl for 30 min and washed with 150ml of 1mM-HCl in a scintered funnel under vacuum before being washed with 20ml of coupling buffer. The washed CNBr-Sepharose was immediately added to the heparin-cHRG solution and gently mixed for 24h at 4°C. A 4ml solution of 2M-ethanolamine in coupling buffer (adjusted to pH 8.0 with 1M-HCl) was added and gently mixed for a further 16h. The slurry was poured into a chromatography column (1.5 x 5.0cm) and washed successively at 4°C with 50ml each of coupling buffer, 0.05M-Tris-HCl buffer, pH 8.0, containing 2M-NaCl and finally PBS. cHRG-Sepharose was stored in PBS at 4°C. Coupling yielded a concentration of 0.8mg protein bound per ml of beads, which bound 6.2 and 3.1 nmol of radiolabelled lung heparin and HS respectively.

Heparanase assay: cHRG-Sepharose beads (0.2ml bed column) were placed in disposable 1 ml syringes tamped with glass wool and the mini-columns placed in 10 ml centrifuge tubes standing in an ice bucket. The columns were pre-washed with 1 ml PBS before use. All column procedures were performed on ice.

To assay for heparanase activity, up to 2µl of sample was added to an incubation mixture consisting of 90pmol of radiolabelled HS in 0.05M-sodium acetate buffer, pH 5.1, containing 5mM-N-acetylmannosamine and 0.1mg/ml BSA in a total volume of 20µl and incubated at 37°C for the appropriate time. The reaction was stopped by freezing the

- 20 -

tubes, 0.3ml cold PBS added, the solution centrifuged if necessary at 4°C and 0.1 ml of the sample applied to a cHRG-Sepharose mini-column pre-equilibrated in PBS. The columns were washed with 0.7 ml PBS, the washings and flow through material transferred to a scintillation vial, 10 ml of scintillation fluid added, and the radioactivity
5 determined. Enzyme activity was expressed as pmol product formed per hour per mg protein or 10^6 cells or ml of serum. The cHRG-Sepharose columns were regenerated by the addition of 1 ml of 0.05M-Tris-HCl buffer, pH 7.5, containing 2M-NaCl and then equilibrated with PBS.

10 Heparanase activity was also detected by gel filtration chromatography of the incubation mixture on a Superose 6 HR 10/30 column (Pharmacia LKB Biotechnology, Uppsala, Sweden), equilibrated in and subsequently developed in PBS. The Pharmacia FPLC system was run at a flow rate of 0.25 ml/min with 0.5 ml fractions collected directly into scintillation vials, to which 3 ml of scintillation fluid was added, and the radioactivity
15 determined. The column was calibrated with ^3H -N-acetylglucosamine (221 Da), bovine lung heparin (12.5 kDa) and heparin-derived Mr ave. standards (16.7, 10.6, 6.7 and 3.1 kDa) which had been partially de-N-acetylated and re-N-acetylated with ^3H -acetic anhydride as described above for the preparation of radiolabelled HS. Radiolabelled chondroitin-6-sulphate and carboxyl-reduced HS (prepared by the method of Karamanos
20 et al, (1988)) were also prepared by the above method.

Binding of HS to cHRG-Sepharose; Samples in $200\mu\text{l}$ of PBS were applied to a mini-column (0.5 x 4.0cm) of cHRG-Sepharose equilibrated in PBS at 4°C. The column was washed with 2ml of PBS and eluted with a linear gradient (2x10mls) of PBS and
25 10mM-sodium phosphate buffer, pH7.2, containing 1.2M-NaCl developed at 0.5ml/min with 0.5ml fractions collected directly into scintillation vials, to which 4ml of scintillation fluid was added and the radioactivity determined. The columns were re-equilibrated in PBS for further use.

III - RESULTS AND DISCUSSION

Preparation of a radiolabelled heparanase substrate.

5 Previous studies of heparanase activity towards heparin or HS have utilized linking reagents to permit radio-iodination (Oosta et al, 1982) which could mask potential cleavage sites, or acetylation of previously de-N-sulphated HS or heparin with radiolabelled acetic anhydride (Nakajima et al, 1986a). However, as was reported, the latter method affected both the apparent Mr of the substrate, and generated heparanase
10 susceptible linkages in heparin, which had previously been shown to be resistant to murine B16 melanoma heparanase activity (Nakajima et al, 1986a). To ensure the production of a radiolabelled, biologically active, natural substrate for the determination of heparanase activity in a variety of biological samples, purified porcine mucosal HS was partially de-N-acetylated and re-N-acetylated with ³H-acetic anhydride to a specific
15 activity of 1650 to 2000 cpm/pmol, which is up to 100 times that previously reported for ¹⁴C labelled HS (Nakajima et al, 1986a). This labelling procedure has the major advantage that there is no introduction of new or altered cleavage sites into the substrate. The substrate was stored at -20°C in 10% (v:v) aqueous ethanol where the substrate was stable for over a year without the production of appreciable degradation products despite
20 repeated freezing and thawing. Porcine mucosal HS which has previously been isolated by Hahnenberger et al (1993) has been shown to have a Mr ave of 22 kDa and to contain heparitinase resistant saccharides of dp 2 to 16, enriched in IdoA2S-GlcNS sequences which mediate bFGF activity (Walker et al, 1994). It also contains extended nitrous acid resistant (GlcNAc-containing) sequences of dp 6 to 14-16 (J.E. Turnbull, unpublished
25 observations) and therefore contains alternating sulphated and non-sulphated regions typical of HS species.

Analysis of heparanase digestion of the HS substrate.

Before a new heparanase assay could be developed, it was essential that the radiolabelled HS be validated as an appropriate substrate using conventional gel filtration
5 to separate and characterise the degradation products. It was also important to define the degradative properties of the heparanase enzymes used in this study. Heparanase degradation of the radiolabelled substrate was assessed using the highly invasive rat mammary adenocarcinoma 13762 MAT and human platelet homogenates, since the tumour and platelet-derived enzymes have previously been shown to have different
10 substrate specificities, degrading either HS only, or both heparin and HS respectively (Nakajima et al, 1988). To prevent subsequent exo-enzyme degradation of the heparanase degradative products, 5mM-N-acetylmannosamine (NAM) was added to the incubation mixture to inhibit release of ³H-labelled N-acetylglucosamine residues following α -N-acetylglucosaminidase activity (Hopwood and Elliott, 1982).

15

HS was incubated with 13762 MAT cell homogenate in the presence of NAM at pH 4.2, 5.1, 6.5 and 7.5 for 16h at 37°C and the reaction mixture was analysed by gel permeation chromatography (Fig.1). The sizes of the heparanase-derived products were compared to a series of radiolabelled heparin-derived Mr standards. HS was maximally
20 degraded at pH 5.1 to fragments with an apparent Mr of 5kDa, compared to apparent Mr of 8 and 16 kDa at pH 6.5 and 7.5 respectively. The rate of degradation at pH 4.2 was slower than at pH 6.5, with a less obvious stepwise breakdown to products. Prolonged incubation of HS with 13762 MAT cell homogenate for 40h again resulted in incomplete degradation at pH 6.5 and 7.5 (data not shown). To determine if different enzyme
25 activities were present or that different cleavage sites were generated at the higher pH values, the individual products of degradation at pH 5.1, 6.5 and 7.5, following a 16h-incubation, were collected, desalted and incubated at either pH 5.1 or 6.5 with fresh homogenate for a further 16h. In each case, each of the tested fragments were degraded to a minimum size of 5 kDa (data not shown). Application of the 5 kDa products of
30 heparanase digestion to DEAE-Sepharose resulted in all of the radioactivity remaining

- 23 -

bound, even in the presence of 0.3M-NaCl, indicating that all the HS fragments resulting from heparanase digestion contained highly sulphated HS domains.

A time course incubation of 13762 MAT cell homogenates with HS at pH 5.1 for periods of 2, 4 and 16h again demonstrated an apparent stepwise degradation of HS (Fig. 2), with three apparent cleavages from 22 to 16 to 8 and finally to 5 kDa. No activity was detected towards chondroitin-6-sulphate or towards carboxyl-reduced HS (CR-HS) following incubation for 16h at pH 5.1, 6.5 or 7.5 (results not shown). Human platelet homogenate heparanase activity similarly did not act on CR-HS but digested HS to fragments of 5 kDa, which were retained by DEAE-Sepharose in 0.3M-NaCl. Homogenates from a variety of cell lines, including the highly metastatic human colonic carcinoma HCT 116 and KM 12-SM lines, human umbilical vein endothelial cells (HUVEC), mouse melanoma B16-F10 cells and a rat liver extract were all demonstrated by gel filtration analysis to hydrolyse HS to fragments of 17, 8 and finally 5 kDa during the course of a 16h incubation (results not shown), indicating that the heparanase activities in each cell lines were cleaving HS to similarly sized products. Previously human platelet, HUVEC, lymphocyte, neutrophil and leukocyte heparanase activities towards bovine endothelial ECM-bound HSPG were also shown to result in the formation of similarly sized HS digestion end products (Vlodavsky et al, 1992).

20

Incubation of extracts of the highly metastatic rat 13762 MAT and DMBA-8A cell lines and the non metastatic variants J-clone and DMBA-Sask with HS resulted in complete degradation of the HS to 5 kDa fragments by the 13762 MAT and DMBA-8A heparanase activities, whereas the J-clone and DMBA-Sask extracts only partially degraded HS to fragments with apparent Mr of 8 and 17 kDa respectively (Fig. 3). The highly metastatic 13762 MAT and DMBA-8A cell lines were previously shown to be more effective in their ability to degrade the artificial basement membrane Matrigel than the J-clone and DMBA-Sask variants in a basement membrane permeability assay (Parish et al, 1992), thus confirming the correlation of metastatic potential with heparanase activity (Nakajima et al, 1983).

25

30

- 24 -

Therefore, porcine mucosal HS is proposed as a suitable natural substrate for the detection of heparanase activity in a variety of cell types, platelets and tissue extracts, and for assessing the heparanase content and the metastatic potential of tumour cell lines. However, due to the multiplicity of cleavage sites the use of gel filtration as a method of separation of products from the undigested substrate makes it difficult to accurately quantify heparanase activity, particularly as multiple cleavages need to occur to allow separation of substrate from product. In addition, it is not known whether the relative rate or each of the cleavages is similar or whether the initial products of digestion may inhibit further cleavage by product inhibition, resulting in a lack of linearity of the assay with respect to time which has been observed for most of the HS degrading exo-activities studied (Freeman and Hopwood, 1986, 1987, 1989a, 1989b). The lack of quantification of the heparanase activity combined with the time and labour required to analyse a single sample by gel filtration analysis highlights the need for a rapid, quantitative heparanase assay capable of detecting a minimum number of substrate cleavages.

15

Development of a quantitative heparanase assay

The interaction of HS- and heparin-binding proteins such as antithrombin III, acidic and basic fibroblast growth factor (FGF), platelet factor 4, β -thromboglobulin and histidine-rich glycoprotein (HRG) with HS has been well documented (Jackson et al, 1991) along with more recent attempts to define their binding motifs on the HS molecule following chemical (primarily nitrous acid degradation) or bacterial heparanase and heparitinase digestion (Turnbull and Gallagher, 1990, 1991; Turnbull et al, 1992; Walker et al, 1994). However, apart from the demonstration that mammalian heparanase can release active bFGF from the ECM (Ishai-Michaeli et al, 1990), little work has been published on the interaction of HS-binding proteins with HS following mammalian heparanase degradation.

While investigating the interaction of chicken HRG (cHRG), an abundant plasma-derived HS-binding protein, with HS it was observed that not only did cHRG mask

- 25 -

the mammalian MAT cell heparanase cleavage sites on HS chains, but following heparanase cleavage of HS, the cHRG-binding motif on HS was lost. Therefore, following heparanase digestion, cleaved HS fragments bound less efficiently to cHRG-coupled Sepharose beads, enabling the development of an efficient and novel method of
5 separating the HS substrate from the products of heparanase digestion.

When HS was applied to a cHRG-Sepharose column and eluted by a salt gradient at pH 7.2, the relatively weakly binding HS was eluted by 0.27M-NaCl (Fig. 4) compared to lung heparin which was eluted by 0.6M-NaCl (results not shown). However, the 5 kDa
10 fragments following complete digestion of HS by a 13762 MAT cell homogenate did not bind to cHRG-Sepharose. When HS was then degraded by 13762 MAT cell heparanase using the standard assay at pH 5.1 for 2, 4 and 16h, the assay mixture was divided into 3 and analysed by gel filtration chromatography, binding to DEAE-Sepharose and binding to cHRG-Sepharose. Gel filtration analysis yielded a similar profile to Fig. 1 with products
15 at 17, 8 and 5 kDa respectively. The application of the assay mixture, and the subsequent elution of radiolabelled HS products from the cHRG-Sepharose column by a salt gradient, demonstrated that the decrease in the apparent Mr of the HS fragments by gel filtration correlated with an increase in material not binding to cHRG-Sepharose (Fig. 4) indicating that the HRG-binding motif on HS was lost following heparanase digestion. There was
20 no apparent change in the affinity of the bound HS fragments towards the cHRG-Sepharose column over the period of the incubation. The binding of HS to cHRG-Sepharose (and the apparent Mr of HS during gel filtration analysis) was not influenced by the assay blanks containing buffer only, 0.1mg/ml BSA, heat inactivated enzyme or active enzyme chromatographed with HS at 4°C (data not shown). Following
25 application of the incubation mixtures to DEAE-Sepharose, all radioactivity remained bound in the presence of 0.3M-NaCl indicating that the products of digestion were not due to desulphation by some endo-sulphatase activity (Bartlett et al, 1995; Dawes and Pepper, 1992; Wells and Dawes, 1995).

- 26 -

To investigate whether the binding of HS to HRG occurs at or in the vicinity of a heparanase sensitive cleavage site, HS was digested with 13762 MAT cell homogenate in the absence and in the presence of a 3:1 molar ratio of cHRG:HS (HS appears to have 3 potential cleavage sites, each of which may bind to a HRG molecule). Fig. 5 shows that in the presence of cHRG, the rate of degradation of HS (resulting in the formation of small (5kDa) fragments) was significantly retarded compared to cleavage in the absence of cHRG where the substrate was completely degraded.

Determination of heparanase activity

10

Using the cHRG-Sepharose assay, maximal heparanase activity was observed at pH 5.1 (results not shown), similar to previous assays analysed by gel filtration (Fig. 1). NAM was added to the incubation mixture to inhibit exo-glycosidase release of ^3H -GlcNAc which would not bind to cHRG-Sepharose. The affinity of HS and the digestion products for cHRG-Sepharose was not influenced by the incubation mixtures containing final concentrations of 0.1mg/ml BSA, 0.1% (v:v) Triton X-100 or up to 0.2M-NaCl. However, tissue homogenate heparanase activity was increased up to 2-fold when assayed in the presence of 0.1% Triton X-100. In contrast, soluble heparanase activity (following removal of the membranes by centrifugation) was unaffected by the addition of BSA or Triton X-100 to the incubation mixture, although highly purified enzyme preparations required the presence of BSA in the incubation mixture for optimal activity and stability. The requirement of BSA for the determination of optimal activity of highly purified enzyme and Triton X-100 for maximal activity of tissue homogenates has been extensively reported for the determination of HS-degrading exo-enzyme activities (Freeman and Hopwood, 1986, 1987, 1989a, b, 1992). The cHRG-Sepharose columns were routinely eluted by high salt concentrations, and re-equilibrated in PBS. The columns were stored in PBS at 4°C and were in constant use for over a 2 year period without appreciable decrease in binding capacity.

15

20

25

- 27 -

Figure 6 compares the change in apparent Mr following 13762 MAT homogenate heparanase digestion of HS (Fig. 6A), with the appearance of unbound radioactive HS fragments following application of the incubation mixture to cHRG-Sepharose (Fig. 6B). Gel filtration analysis of material not bound to cHRG-Sepharose following a 6h incubation
5 showed an apparent Mr of 17 kDa (results not shown). Enzyme activity determined by cHRG-Sepharose analysis was linear with respect to time for up to 10h incubation and for up to 30% conversion substrate to product (Fig 6B). Following prolonged (24 h) incubation, 84% of the radioactivity passed through the cHRG-Sepharose column and had an apparent Mr of 5 kDa. Material remaining bound to the column presumably contained
10 higher affinity HRG- binding motifs or was heparanase resistant, a phenomenon which was not investigated. Background material not binding to cHRG-Sepharose was generally of low Mr, being less than 6 kDa, and may represent previously cleaved HS fragments obtained during isolation of the HS from the porcine mucosa. The fragments may be removed by prior affinity purification of the HS substrate using cHRG-Sepharose, or by
15 prior gel filtration to remove the smaller Mr species.

Human HRG (hHRG)-Sepharose can be used satisfactorily in place of cHRG-Sepharose for the determination of heparanase. However, the binding affinity of hHRG for BALB/c 3T3 cell surface HSPG was weaker than that observed for cHRG (Brown and
20 Parish 1994) and this was reflected by a higher affinity of cHRG-Sepharose for porcine mucosal HS than that observed for hHRG-Sepharose (results not shown). Chicken HRG has the additional advantage that it can be purified in higher yield from plasma than hHRG (C. Parish, unpublished observations). Commercially available bovine kidney HS (Mr 17 kDa) can be used in place of porcine intestinal HS for the determination of
25 heparanase activity. In contrast, commercial bovine intestinal HS cannot be used for the determination of heparanase activity as it has a Mr less than 5 kDa, and is essentially not mammalian heparanase sensitive by both gel filtration and cHRG-Sepharose analysis.

Analysis of heparanase activity in different biological samples

A variety of cell lines, tissues and platelet homogenates as well as serum from normal and cancer patients were tested for heparanase activity using the quantitative
5 CHRG-Sepharose heparanase assay. Table 1 shows that the heparanase activity present in homogenates of the highly metastatic rat mammary adenocarcinoma 13762 MAT and DMBA-8A cell lines was 4- and 10-fold higher than for the respective non-metastatic J-clone and DMBA-Sask variants. These values closely correlate with both the relative
10 ability of these cell lines to degrade an artificial (Matrigel) basement membrane (Parish et al, 1992) and for the cell homogenates to degrade HS as assessed by gel filtration analysis (see earlier). The metastatic variants of the murine Lewis lung carcinoma (D122) and lung carcinoma (A3a) degraded HS 2.5- and 4.8-fold faster than their respective non-metastatic variants (Table 1). Previously, Nakajima et al, (1986a, b) had reported only a 1.5- to 2.2-fold difference in heparanase activity between extracts of the poorly metastatic B16-F1
15 sub-line compared to the more highly metastatic B16-BL6, -F10 and -B16b sub-lines using their solid phase assay with deN-sulfated, reN-acetylated HS.

The sensitivity of the heparanase assay of the present invention may be of use for the clinical assessment of cancer patients. Heparanase activity was determined in lung
20 tumour tissue taken from six lung carcinoma patients. Of these, heparanase activity in the primary tumour of five patients was elevated from 2- to 4- fold compared to that from the patient's adjacent non-tumourous lung tissue (results not shown). Although heparanase activity was barely detectable in human plasma (less than 4 pmol/hr/ml plasma), significant heparanase activity was detected in normal adult sera and in sera from patients
25 with metastatic malignancies. Serum heparanase activity in the cancer patients tested was 2-fold higher than that observed for normal controls (229.7 ± 28.8 (n=8) for cancer patients compared to 116.6 ± 13.3 (n=5) pmol/hr/ml serum for controls), confirming the results observed for sera from malignant melanoma patients (Nakajima et al, 1988). In fact, these authors observed a 4-fold increase in serum heparanase activity in patients
30 where tissue metastases were present. Nakajima et al (1986c, 1988) also observed that

- 29 -

heparanase serum levels in rats were 17-fold higher than normal 30 days after injection of the highly metastatic 13762NF mammary adenocarcinoma cells while enzyme activities in the sera of rats bearing MTLn3 tumours correlated well with the extent of the metastases.

5

Heparanase activity was also detected in a variety of human and rat cell lines, platelets and tissue homogenates (Table 2) which should represent valuable sources of the heparanase enzyme for future purification. For ease of comparison between cells and tissues heparanase activity is expressed/mg of protein extracted. The development of this
10 rapid, and quantitative heparanase assay will be invaluable for the purification of heparanase activity from a variety of sources and will enable the rapid screening of putative heparanase inhibitors.

TABLE 1 Heparanase activity of metastatic and non-metastatic tumour cell lines

Tumour cell homogenate heparanase activity was assessed following fractionation of the incubation mixture on cHRG-Sepharose. Enzyme activity is expressed as mean \pm SEM for three separate experiments except where otherwise designated. For full details, see the Methods section.

Tumour type	Cell line	Metastatic	Heparanase activity (pmol/hr/10 ⁶ cells)
Rat mammary adenocarcinoma	13762 MAT	Yes	47.4 \pm 2.2
	13762 MAT (J-clone)	No	12.8 \pm 0.5
	DMBA-8A	Yes	35.6 \pm 3.2
	DMBA-Sask	No	3.4 \pm 0.1
Human colonic carcinoma	HCT 116	Yes	10.3, 10.4
Human monocyte	U937	No	7.6, 8.2
Human keratinocyte	KJD	No	7.8, 10.2
Murine Lewis lung carcinoma	D122	Yes	16.4 \pm 1.1
	LLC	No	6.5 \pm 0.5
Murine lung carcinoma	A3a	Yes	16.3 \pm 1.2
	SP1	No	3.4 \pm 0.2

- 31 -

TABLE 2 Heparanase activity in human and rat cells and tissues.

The range of heparanase activity in a variety of homogenates of human and rat tissue and cultured cells was assessed following fractionation of the incubation mixture on cHRG-Sepharose. For full details, see the Methods section.

Cell or tissue	Heparanase activity (pmol/hr/mg protein)
Human platelets	2178 - 3591 (n = 6)
Human colonic carcinoma (HCT 116)	38.2 - 66.6 (n = 4)
HUVECS	21.0 - 42.6 (n = 4)
Human smooth muscle cells	50.3, 75.9
Human lung fibroblasts	1.5, 3.0
Human keratinocyte (KJD)	62.2, 78.4
Rat 13762 MAT cells	141.1 - 349.2 (n = 6)
Rat liver	9.5 - 28.3 (n = 6)

EXAMPLE 2

Abbreviations used: BSA bovine serum albumin; cHRG, chicken histidine-rich glycoprotein; HRC, histidine-rich glycoprotein; HS, heparan sulphate; HSPG, heparan sulphate proteoglycan; HUVEC, human umbilical vein endothelial cells; PBS, phosphate buffered saline.

I -MATERIALS

10

Heparin-derived molecular mass ($M_{r_{ave}}$) standards of 16.7, 10.6, 6.7 and 3.1kDa were a generous gift from Nova Nordisk (Gentofte, Denmark) (see Kristensen et al, 1991). Porcine mucosal HS (ORG 553) was a generous gift from Organon Int. Bv,(Oss, The Netherlands). Pharmacia Fine Chemicals (Uppsala, Sweden) supplied concanavalin A-
15 Sepharose 4B, chelating-Sepharose 4B, Superose 6 and 12 HR 10/30 gel chromatography

- 32 -

columns, molecular mass standard kits for standardising gel filtration columns and SDS-PAGE gels, and octyl-Sepharose. Sigma Chemical Co. (St Louis, MO) supplied crystalline bovine serum albumin (BSA), bovine lung and porcine mucosal heparin, bovine kidney HS, 3,3-dimethyl glutaric acid, Blue A-agarose, octyl-agarose, CHAPS, zinc acetate, 5 Amicon Corp. (Beverly, MA) supplied Centricon 100 and 30 microconcentrators. Beckmann (Gladesville, Australia) supplied Ready Safe scintillation fluid. Stratagene USA (La Jolla, CA) supplied StrataClean Resin.

Expired platelet-rich plasma was obtained from the Canberra Hospital, washed 10 twice with normal saline by centrifuging the suspended platelets at 1600 x g for 15 min at 20°C and the pellet stored frozen at -80°C. Human platelets were also obtained by the method of Bartlett et al (1995) and washed twice in normal saline. Cell homogenates were prepared by suspending 10⁶ platelets in 0.2ml of 0.1% (v:v) aqueous Triton X-100 and disrupting by freezing and thawing three times in a solid-CO₂/ethanol mixture. Protein 15 concentrations were estimated by a Bio-Rad Coomassie protein assay kit (Bio-Rad Laboratories, Richmond, CA) using BSA as a standard.

II -METHODS

20 Preparation of radiolabelled substrates

Radiolabelled porcine intestinal mucosal heparan sulphate (ORG 553), porcine intestinal mucosal and bovine lung heparin were prepared by the method of Example 1 by N-deacetylation with hydrazine and N-acetylation with ³H-acetic anhydride.

25

Heparanase assays:

Assay 1. Human platelet heparanase activity was determined towards HS and the products separated from the substrate using the chicken histidine-rich glycoprotein 30 (cHRG)-Sepharose beads separation method of Example 1. Up to 2 μ l of sample was

- 33 -

added to an incubation mixture consisting of 90pmol of radiolabelled HS in 0.05M-sodium acetate buffer, pH 5.1, containing 5mM-N-acetylmannosamine and 0.1mg/ml BSA in a total volume of 20 μ l and incubated at 37°C for the appropriate time to yield between 5 and 20% breakdown of the substrate to products. The reaction was stopped by freezing
5 the tubes, 0.3ml cold phosphate-buffered saline (PBS) added, the solution centrifuged if necessary at 4°C and 0.1ml of the sample applied to a cHRG-Sepharose mini-column (0.2ml) pre-equilibrated in PBS. The columns were washed with 0.7ml PBS, the washings and flow through material transferred to a scintillation vial, 10ml of scintillation fluid added, and the radioactivity determined. Enzyme activity was expressed as pmol product
10 formed per hour per mg protein.

Assay 2. Heparanase activity towards 2 μ g of the radiolabelled HS or heparin analogues was assayed as described above for 16h at 37°C, and detected by gel filtration analysis of the incubation mixture on either Superose 6 (for HS degradation) or Superose 12 (for
15 heparin degradation). The chromatography columns were both equilibrated in and developed with PBS at a flow rate of 0.25ml/min with 0.5ml fractions being collected directly into scintillation vials, to which 3ml of scintillation fluid was added, and the radioactivity determined. The columns were calibrated with ³H-N-acetylglucosamine (221 Da), bovine lung heparin (12.5kDa) and heparin-derived $M_{r_{ave}}$ standards (16.7, 10.6, 6.7
20 and 3.1 kDa) which had been partially de-N-acetylated and re-N-acetylated with ³H-acetic anhydride as described above for the preparation of radiolabelled HS.

Purification of platelet heparanase

25 All procedures were performed at 4°C unless otherwise stated. Heparanase activity towards HS was determined using assay 1. In each step (except for the 0.8M-NaCl wash of Blue A-agarose in Step 3), the buffer washes of the columns continued until no more protein was detected in the column eluate using a Bio-Rad protein assay.

- 34 -

- Step 1.** Solubilisation of enzyme activity: Fifty units of frozen, washed human platelets were allowed to thaw by suspension in 4 volumes of 15mM-sodium dimethylglutarate buffer, pH 6.0, containing 0.5M-NaCl (buffer A), and the sample freeze/thawed three times following immersion in a solid CO₂/ethanol bath. The suspended platelet homogenate was centrifuged at 35000 x g for 60 min and the supernatant used in Step 2. The pelleted material was resuspended in 200ml of buffer A, freeze/thawed once again and centrifuged as before. This procedure was repeated twice more before the final pellet was homogenised in buffer A containing 1% (v:v) CHAPS and centrifuged as before. Heparanase activity in the CHAPS supernatant was purified exactly as described below except for the addition of Triton X-100 to the extract in Step 2.
- Step 2.** Concanavalin A-Sepharose chromatography: The supernatant from Step 1 was made 0.2% in Triton X-100 (v:v) and applied at approximately 1ml/min to a concanavalin A-Sepharose column (1.5 x 5.0cm) equilibrated in buffer A containing 0.2% Triton X-100 (buffer B). The column was washed in turn with 25ml of buffer B and 40mls of buffer A at 4°C before being washed with 40ml of buffer A which had been prewarmed to 20°C. Heparanase activity was eluted by the application of 40ml of buffer A containing 20% α -methyl mannoside (w:v), which had been prewarmed to 20°C. The eluate was collected into a container held in an ice bucket.
- Step 3.** Zn²⁺-chelating Sepharose/Blue A-agarose chromatography: The enzyme solution from Step 2 was applied at 1ml/min to a Zn²⁺-chelating Sepharose column (1.0 x 10.0cm) connected in series with a Blue A-agarose column (1.0 x 2.0cm). The combined columns were washed with 50ml of buffer A, before the disconnected Blue A-agarose column was washed in turn with 20ml of Tris buffer (60mM-Tris/HCl buffer, pH 7.4, made up in 10% (v:v)

- 35 -

glycerol) containing 0.5M-NaCl, and 1.5ml of Tris buffer containing 0.8M-NaCl.

Step 4. Blue A-agarose/octyl-agarose chromatography: The Blue A-agarose column in Step 3 was connected to an octyl-agarose column (1.0 x 1.5cm) which was equilibrated in Tris buffer containing 2M-NaCl. The Blue A-agarose column was eluted at 0.5 ml/min by 15 ml of Tris buffer containing 2M-NaCl. The octyl-agarose eluate was immediately concentrated to 5ml in volume in an Amicon ultrafiltration stirred cell containing a PM10 membrane before being concentrated to 0.2ml in volume by Centricon 30 centrifugation. Buffer A containing 10% (v:v) of glycerol (buffer C) was added and the enzyme solution concentrated again to 0.4ml.

Step 5. Superose 12 chromatography: The concentrated enzyme solution from Step 4 was applied in two separate lots of 200 μ l to two Superose 12 HW 10/30 columns connected in series and equilibrated in and developed with buffer C at 0.5ml/min. Fractions of 0.5ml were collected assayed for heparanase activity and fractions containing heparanase activity were concentrated to 0.4ml by Centricon 30 centrifugation. The purified enzyme was stable for months when stored in buffer C at 4°C.

Step 6. Centricon 100 and 30 centrifugation: For platelet preparations obtained from less than 20 units of washed platelets, the 2M-NaCl eluate from the octyl-Sepharose column in Step 4 was concentrated by centrifugation in a Centricon 100 microconcentrator and the filtrate containing the heparanase activity was concentrated and dialysed against buffer C using a Centricon 30 microconcentrator as described in Step 4.

- 36 -

Native and subunit Mr

The native Mr of purified human platelet heparanase activity was determined by chromatography on two Superose 12 HW 10/30 columns connected in series as described in Step 5 above. The columns were calibrated with the following Mr standards: thyroglobulin (669kDa), ferritin (440kDa), catalase (232kDa), fructose-biphosphate aldolase (158kDa), bovine serum albumin (67kDa), ovalbumin (43kDa), chymotrypsinogen (25kDa) and ribonuclease A (13kDa).

10 Discontinuous SDS-PAGE were run according to the method of Laemmli (1981) and stained with Coomassie Brilliant Blue R250. The 10% polyacrylamide gels were calibrated with the following Mr standards: phosphorylase b (94kDa), bovine serum albumin (67kDa), ovalbumin (43kDa), carbonic anhydrase (30kDa), soya-bean trypsin inhibitor (20kDa) and α -lactalbumin (14kDa). Samples were concentrated by the addition
15 of 10ul of StrataClean Resin, vortexing and centrifuging the suspension according to the manufacturer's instructions. The pelleted material was reduced by boiling in dithiothreitol, and the suspension applied to the stacking gel by the standard procedure.

III - RESULTS AND DISCUSSION

20

Purification of platelet heparanase

Previously, it has been shown that human platelet homogenates contained 2.2-3.6 nmol/h/mg protein heparanase activity towards HS, a 60-fold higher activity compared to
25 that observed in the metastatic human colonic carcinoma tumour cell line HCT 116 (Example 1). Therefore platelets are an extremely rich source of mammalian heparanase activity. Heparanase activity can be released from freshly obtained platelets by thrombin-induced degranulation (Hoogewerf et al, 1995), but it has been observed that the level of heparanase activity released by thrombin stimulation of out of date platelets was quite

- 37 -

variable. Therefore heparanase activity was obtained by solubilisation by the freeze/thawing of previously frozen washed platelets.

Because of the reported instability of the enzyme (Oldberg et al, 1980) and the relatively low recoveries of activity obtained during purification of the enzyme (Hoogewerf et al, 1995; Oosta et al 1982), chromatography conditions were developed to maximise the concentration of the eluted protein. This was achieved by batch (or isocratic) rather than gradient elution, and devising conditions where the enzyme would pass unbound through one column to be bound by the next column in series. This allowed a saving in the time taken to assay for the enzyme activity following a salt gradient elution and minimised the loss of activity due to dilution of the enzyme.

Homogenisation of the previously frozen washed platelets in buffer A (which contained 0.5M-NaCl) did not release any appreciable soluble enzyme activity. Approximately 75% of the total heparanase activity, however, was solubilized by repeated freeze/thawing of the platelets followed by centrifugation of the homogenate (Table 3). The remaining membrane associated enzyme could only be released by homogenisation in buffer A containing 1% (v:v) CHAPS. Homogenisation of the membranes with buffer A containing 1% Triton X-100 solubilised the enzyme, but it rapidly lost activity. The membrane bound enzyme was purified from 50 units of washed platelets by the same procedure used to isolate the soluble enzyme.

All of the enzyme activity applied to the concanavalin A-Sepharose column was tightly bound when applied in the presence of detergent. Washing the column by application of buffer A at 20°C removed more non-specifically bound protein than by washing the column at 4°C alone. The recovery of enzyme activity and speed of elution (in less than five column volumes of eluant) was greatly enhanced by elution of the column at 20°C, compared to the normal elution at 4°C. Heparanase activity was purified by 19-fold with a recovery of 56% from the original platelet supernatant (Table 3). The recovery of enzyme activity from this Step was generally in the range of 55 to 70%. No

- 38 -

further heparanase activity was eluted from the column by buffer containing α -methyldmannoside and 0.1% Triton X-100 at 20°C. The use of chelating-Sepharose and dye-matrix chromatography, which has been so successfully used to purify HS-degrading exo-enzyme activities (Bielicki et al, 1990; Clements, et al 1985; Freeman and Hopwood, 5 1986, 1987, 1989), has not been previously used to isolate mammalian heparanase activity. The enzyme, which did not bind to the zinc-chelating column, was tightly bound to the dye column which permitted a complete separation of the heparin-degrading exo-enzyme activities α -L-iduronidase, β -D-glucuronidase and α -N-acetylglucosaminidase from the platelet heparanase (results not shown). No heparanase activity was detected in 10 the unbound fraction, or in the low salt (0.5 and 0.8M-NaCl) Tris buffer washes of the dye column. High salt (2M-NaCl) elution of heparanase from the Blue A-agarose column resulted in most of the contaminating protein binding to the octyl-agarose column, while the unbound heparanase was concentrated in an almost pure form for a final purification by gel chromatography. Whereas the enzyme did not bind to octyl-agarose, it did bind to 15 octyl-Sepharose when applied in 2M-NaCl, but was eluted from the column in 1M-NaCl (results not shown). Heparanase activity was purified a further 80-fold over step 2, giving an overall purification of 1500-fold with a recovery of 26% of activity. No further activity was recovered from the chelating-Sepharose column or from the octyl-agarose column following elution of the rest of the bound protein from the columns with buffer 20 A containing 0.1M-imidazole and 1% Triton X-100 respectively. Furthermore, no heparanase activity was detected in the filtrate following Centricon 30 concentration of the almost pure enzyme in contrast to that reported by Hoogewerf et al (1995).

Gel filtration chromatography (Fig. 7) resulted in a final 1.1-fold purification of the 25 enzyme over Step 4, resulting in a final 1900-fold purification with 19% recovery of activity from the original homogenate. This compares with a 240000-fold purification in 5.6% yield and a 4100-fold purification in 8% yield from platelet-rich plasma reported by Oosta et al (1982) and Hoogewerf et al (1995) respectively. Smaller preparations of the purified human platelet heparanase (using less than 20 units of washed platelets), could 30 be prepared within 2 days in up to 30% yield using the method described in this Example.

- 39 -

In this case, proportionally smaller columns are used and the gel filtration Step 5 replaced by filtering the octyl-agarose eluate through a Centricon 100 to be concentrated by a Centricon 30 filter. The membrane associated enzyme was also purified with 25% recovery of enzyme activity with a specific activity of 6600 nmol/h/mg of protein, similar to that observed for the soluble enzyme. The membrane associated form of the enzyme exhibited the same chromatographic properties as the soluble form of the enzyme.

Native molecular mass

10 Gel filtration analysis of both purified heparanase (see Fig.7) and of enzyme obtained following concanavalin A-Sepharose chromatography (Step 2) demonstrated that the enzyme has an apparent Mr of 50kDa. No enzyme activity was detected in either case at Mr values corresponding to 8-10kDa or dimers or tetramers of the chemokine sized platelet heparanase activity as reported by Hoogewerf et al (1995), nor was any
15 activity detected that corresponded to an apparent Mr of 134kDa as reported by Oosta et al (1982). The results presented in this Example, however, are similar to the Mr value of 40-60kD obtained by Graham and Underwood (1996) for human platelet extracts. This value is also similar to the 45kDa native Mr reported for purified human placental heparanase (Gilat et al , 1995) and 50kDa reported for partially purified human spleen
20 heparanase (Sewell et al, 1989), but differs from the Mr value of 94kDa reported for the murine melanoma enzyme (Jin et al, 1990). Furthermore, purified human heparanase was not retained by Centricon 100kDa membranes, but was retained by Centricon 30kDa membranes. No heparanase activity was detected in the 30kDa membrane filtrate as reported by Hoogewerf et al (1995). However, following Step 2 chromatography, enzyme
25 activity was retained by Centricon 100kDa membranes indicating substantial interaction with other proteins during the process of concentration since the Step 2 material had an apparent Mr of 50kDa by gel filtration analysis (results not shown). SDS-PAGE analysis of the purified enzyme indicated a single Coomassie blue staining band corresponding to a Mr value of 50kDa under both reducing (Fig 8) and non-reducing conditions (results not
30 shown), which was identical to the value obtained by gel filtration analysis. The purified

- 40 -

membrane associated enzyme also had a native Mr and subunit Mr of 50kDa as determined by gel filtration and SDS-PAGE analysis (under reducing conditions). It is not known how the enzyme is associated with the membrane. Because its size is similar to the soluble enzyme, it is possible that heparanase may exist in both soluble and
5 membrane associated forms similar to the lysosomal enzyme acid phosphatase, which is transported to the lysosome by a mannose-6-phosphate independent pathway, and which has a 2kDa C-terminal transmembrane peptide which results in the enzyme existing in the lysosome as both a membrane bound and soluble forms. (Peters et al, 1990). Previously, Gallagher et al (1988) reported the presence of a rat liver membrane
10 heparanase activity. However, unlike the enzyme reported here, that enzyme was inactive at pH values less than 7.5.

Substrate specificity of purified platelet heparanase.

15 Purified human platelet heparanase activity towards HS, as determined by assay 1, was maximal at pH 5.1 similar to that reported for the platelet homogenate heparanase activity (Example 1). The purified enzyme cleaved both HS and heparin following analysis of the assay by gel filtration. Porcine mucosal HS (22kDa), and bovine kidney HS (17kDa) were each cleaved to 5kDa fragments as reported for platelet homogenate
20 heparanase activity towards the mucosal HS (Example 1). Previously, porcine mucosal HS was shown to be cleaved in a stepwise fashion from 22 to 17 to 11 and finally to 5kDa fragments (Example 1).

Mucosal heparin and the more highly sulphated lung heparin were each cleaved
25 from 12.5kDa to 4 and 6kDa fragments respectively. Mucosal heparin appeared to be cleaved twice in a stepwise fashion compared to the singularly cleaved lung heparin. Unlike the report of Hoogewerf et al (1995), however, there was no evidence of the production of the predominately disaccharide products resulting from the cleavage of HS or heparin (or modified heparins) following prolonged incubations of either purified

enzyme or Step 1 homogenate heparanase, even after pre-treatment of the enzyme with reducing and oxidising agents as described by those authors.

TABLE 3 Purification of Heparanase from Human Platelets.

	Step	Heparanase activity (nmol/h)	Total Protein (mg)	Specific activity (nmol/h/mg)	Purification (-fold)	Yield (%)
1.	Homogenate	12192	3465	3.52	-	-
	Supernatant	9892	2098	4.72	1	100.0
	Pellet	4480	552	8.12	(1.7)	-
2.	Concanavalin A-Sepharose	5523	63.1	87.53	18.5	55.8
3.	Zn-Sepharose/ Blue A-agarose/					
4.	Octyl-agarose	2579	0.37	6970.3	1476.7	26.1
5.	Superose 12	1873	0.24	7804.2	1653.4	18.9

REFERENCES

- Bar-Ner, M., Kramer, M. D., Schirmacher, V., Ishai-Michaeli, R., Fuks, Z., and Vlodavsky, I. (1985). *Int. J. Cancer* **35**, 483-491.
- Bar-Ner, M., Mayer, M., Schirmacher, V., and Vlodavsky, I. (1986). *J. Cell. Physiol.* **128**, 299-306.
- Bartlett, M. R., Cowden, W. C. and Parish, C. R. (1995a). *J. Leukocyte. Biol.* **57**, 207-213.
- Bartlett, M. R., Underwood, P. A., and Parish, C. R. (1995b). *Immunol. Cell Biol.* **73**, 113-124.
- Benezra, M., Vlodavsky, I., and Bar-Shavit, R. (1992). *Exp. Cell. Res.* **201**, 208-215.
- Bielicki, J., Freeman, C., Clements, P. R. and Hopwood, J. J. (1990). *Biochem. J.* **271**, 75-86.
- Brenan, M., and Parish, C. R. (1986). *Eur. J. Immunol.* **16**, 423-430.
- Brown, K. J., and Parish, C. R. (1994). *Biochemistry* **33**, 13918-13927.
- Castellot Jr., J. J., Favreau, L. V. Karnovsky, M. J. and Rosenberg, R. D. (1982) *J. Biol. Chem.* **257**, 11256-11260.
- Clements, P. R., Brooks, D. A., Saccone, G. T. P. and Hopwood, J. J. (1985). *Eur. J. Biochem.* **152**, 21-28.
- Coombe, D.R., Parish, C.R., Ramshaw, I.A. and Snowden, J.M. (1987). *Int. J. Cancer*, **39**, 82-88.

Crissman, J. D., Hatfield, J., Shaldenbrand, M., Sloane, B. F. and Honn, K. V (1985). *Lab. Invest.* **53**, 470-478.

Dawes, J., and Pepper, D. S. (1992). *Thromb. Haem.* **67**, 468-472.

Eldor, A., Bar-Ner, M., Yahalom, J., Fuks, Z. and Vlodavsky, I. (1987). *Sem. Thromb. Haem.* **13**, 475-488.

Freeman, C., and Hopwood, J. J. (1986). *Biochem. J.* **234**, 83-92.

Freeman, C., and Hopwood, J. J. (1987). *Biochem. J.* **246**, 355-365.

Freeman, C., and Hopwood, J. J. (1989a). *Anal. Biochem.* **176**, 244-248.

Freeman, C., and Hopwood, J. J. (1989b). *Biochem J.* **259**, 209-216.

Freeman, C., and Hopwood, J. J. (1991). *Biochem. J.* **279**, 399-405.

Freeman, C., and Hopwood, J. J. (1992). *Biochem. J.* **282**, 605-614

Gallagher, J. T., Walker, A., Lyon, M., and Evans, W. H. (1988). *Biochem. J.* **250**, 719-726.

Gamse, G., Fromme, H. G. and Kresse, H. (1978). *Biochim. Biophys. Acta.* **544**, 514-528.

Gilat, D., Hershoviz, R., Goldkorn, I., Cahalon, L., Vlodavsky, I. and Lider, O. J. (1995). *J. Exp. Med.* **181**, 1929-1934.

Godder, K., Vlodavsky, I., Eldor, A., Weksler, B. B., Haimovitz-Freidman, A., and Fuks, Z. (1991). *J. Cell. Physiol.* **148**, 274-280.

Graham, L. D., Hayward, I. P. and Underwood, P. A. (1995a). *Biochem. Mol. Biol. Int.* **37**, 231-237.

Graham, L. D., Mitchell, S. M. and Underwood, P. A. (1995b). *Biochem. Mol. Biol. Int.* **37**, 239-246.

Graham, L. D. and Underwood, P. A. (1996). *Biochem. Mol. Biol. Int.* **39**, 563-571.

Hahnenberger, R., Jakobsen, Å. M., Ansari, A., Wehler, T., Svahn, C. M. and Lindahl, U. (1993). *Glycobiology* **3**, 567-573.

Hennes, R., Frantzen, F., Keller, R., Schirmacher, V. and Schwartz-Albiez, R. (1988). *Br. J. Cancer.* **58**, 186-188.

Hoogewerf, A. J., Leone, J. W., Reardon, I. M., Howe, W. J., Asa, D., Henrikson, R. L., and Ledbetter, S. R. (1995). *J. Biol. Chem.* **270**, 3268-3277.

Hopwood, J. J., and Elliott, H. (1982). *Clin. Chim. Acta.* **120**, 77-86.

Höök, M., Wasteson, Å., and Oldberg, Å. (1975). *Biochem. Biophys. Res. Commun.* **67**, 1422-1428.

Irimura, T., Nakajima, M., and Nicolson, G. L. (1986). *Biochemistry* **25**, 5322-5328.

Ishai-Michaeli, R., Eldor, A., and Vlodavsky, I. (1990). *Cell Regul.* **1**, 833-842.

Jackson, R.L., Busch, S. J. and Cardin, A.D. (1991). *Physiol. Rev.* **71**, 481-539.

Jin, L., Nakajima, M. and Nicolson, G. L. (1990). *Int. J. Cancer.* **45**, 1088-1095.

- 45 -

Karamanos, N. K., Hjerpe, A., Tsegenidis, T., Engfeldt, B., and Antonopoulos, C. A. (1988). *Anal. Biochem.* **172**, 410-419.

Klein, U., and von Figura, K. (1976). *Biochem. Biophys. Res. Commun.* **73**, 569-576.

Klein, U., and von Figura, K. (1979). *Hoppe-Seyler's Z. Physiol. Chem.* **360**, 1465-1471

Kristensen, H. I., Tromborg, E. M., Nielsen, J. R., Nielsen, J. I., Johansen, K. B. and Ostergaard, P. B. (1991). *Thromb. Res.* **64**, 131-141.

Laemmli, U. K. (1970). *Nature (London)* **227**, 680-685.

Lane, D. A., Pejler, G., Flynn, A. M., Thompson, E. A., and Lindahi, U. (1986). *J. Biol. Chem.* **261**, 3980-3986.

Laskov, R., Ishai-Michaeli, R., Sharir, H., Yefenof, E., and Vlodavsky, I. (1991). *Int. J. Cancer* **47**, 92-98.

Lider, O., Baharav, E., Mekori, Y. A., Miller, T., Naparstek, Y., Vlodavsky, I., and Cohen, I.R. (1989). *J. Clin. Invest.* **83**, 752-756.

Matzner, Y., Bar-Ner, M., Yahalom, J., Ishai-Michaeli, R., Fuks, Z., and Vlodavsky, I. (1985). *J. Clin. Invest.* **76**, 1306-1313.

Matzner, Y., Vlodavsky, I., Bar-Ner, M., Ishai-Michaeli, R., and Tauber, A. I. (1992). *J. Leukoc. Biol.* **51**, 519-524.

Morikawa, K., Walker, S. M., Nakajima, M., Pathak, S., Jessup, J.M. and Fidler, I. J. (1988). *Cancer Res.* **48**, 6863-6871.

- 46 -

Nakajima, M., Irimura, T., Di Ferrante, D., Di Ferrante, N., and Nicolson, G. L. (1983). *Science* **220**, 611-613.

Nakajima, M., Irimura, T., and Nicolson, G. L. (1986a). *Anal. Biochem.* **157**, 162-171.

Nakajima, M., Irimura, T., and Nicolson, G. L. (1986b). *Cancer Lett.* **31**, 277-283.

Nakajima, M., Welch, D. R., Irimura, T., and Nicolson, G. L. (1986c). *Prog. Clin. Biol. Res.* **212**, 113-122.

Nakajima, M., Irimura, T., and Nicolson, G. L. (1988). *J. Cell. Biochem.* **36**, 157-167.

Naparstek, Y., Cohen, I. R., Fuks, Z., and Vlodavsky, I. (1984). *Nature* **310**, 241-243.

Oldberg, Å, Heldin, C-H., Wasteson, Å., Busch, C., and Höök, M. (1980). *Biochemistry* **19**, 5755-5762.

Oosta, G. M., Favreau, L. V., Beeler, D. L., and Rosenberg, R. D. (1982). *J. Biol. Chem.* **257**, 11249-11255.

Parish, C. R., Jakobsen, K. B., and Coombe, D. R. (1992). *Int. J. Cancer* **52**, 378-383.

Parish, C., Willenborg, D., and Cowden, W. (1990). *Today's Life Sci.* **2**, 20-27.

Peters, C., Braun, M., Weber, B., Wendland, M., Schmidt, B., Pohlmann, R., Waheed, A. and von Figura, K. (1990) *EMBO J.* **9**, 3497-3506.

Ricoveri, W., and Cappelletti, R. (1986). *Cancer Res.* **46**, 3855-3861.

Rylatt, D. B., Sia, D. Y., Mundy, J. P., and Parish, C. R. (1981). *Eur. J. Biochem.* **119**, 641-646.

Schlechte, W., Murano, G., and Boyd, D. (1989). *Cancer Res.* **49**, 6064-6069.

Schmitt, M., Janicke, F., and Graeff, J. (1992). *Fibrinolysis* **6**, (Suppl 4), 3-26.

Sewell, R. F., Brenchley, P. E. G., and Mallick, N. P. (1989). *Biochem. J.* **264**, 777-783.

Thunberg, L., Bäckström, G., Wasteson, Å., Robinson, H. C., Ögren, S., and Lindahl, U. (1982). *J. Biol. Chem.* **257**, 10278-10282.

Turnbull, J. E., and Gallagher, J. T. (1990). *Biochem. J.* **265**, 715-724.

Turnbull, J. E., and Gallagher, J. T. (1991). *Biochem. J.* **273**, 553-559.

Turnbull, J. E., Fernig, D. G., Ke, Y., Wilkinson, M. C., and Gallagher, J. T. (1992). *J. Biol. Chem.* **267**, 10337-10341.

Vlodavsky, I., Eldor, A., Haimovitz-Friedman, A., Matzner, Y., Ishai-Michaeli, R., Lider, O., Naparstek, Y., Cohen, I. R., and Fuks, Z. (1992). *Invasion Metastasis* **12**, 112-127.

Vlodavsky, I., Ishai-Michaeli, R., Bar-Ner, M., Fridman, R., Horowitz, A. T., Fuks, Z., and Biran, S. (1988). *Isr. J. Med. Sci.* **24**, 464-470.

Walker, A., Turnbull, J. E., and Gallagher, J. T. (1994). *J. Biol. Chem.* **269**, 931-935.

Wasteson, A., Glimelius, B., Busch, C., Westermarck, B., Heldin, C-H. and Norling, B. (1977). *Thromb. Res.* **11**, 309-321.

Wasteson, A., Hook, M. and Westermark, B. (1976). *FEBS Letters*, **64**, 218-221.

Wells, X. E., and Dawes, J. (1995). *Thromb. Haem.* **74**, 667-672.

Willenborg, D. O., and Parish, C. R. (1988). *J. Immunol.* **140**, 3401-3405.

Yahalom, J., Eldor, A., Biran, S., Fuks, Z. and Vlodavsky, I. (1985). *Radiother. Oncol.* **3**, 211-225.

Yahalom, J., Eldor, A., Fuks, Z. and Vlodavsky, I. (1984) *J. Clin. Invest.* **74**, 1842-1849.

Yurchenco, P. D., and Schittny, J. C. (1990). *FASEB J.* **4**, 1577-1590.

CLAIMS:

1. A method for the detection of mammalian heparanase activity in a sample, which comprises the steps of:
 - i. contacting the sample to be tested with a heparanase substrate for a time and under conditions sufficient for heparanase in the sample to degrade the heparanase substrate;
 - ii. separating degradation products from undegraded or partially degraded heparanase substrate by binding the undegraded or partially degraded heparanase substrate with a heparan sulphate-binding protein; and
 - iii. detecting separated degradation products to indicate heparanase activity in the sample.
2. A method according to claim 1, wherein said sample is selected from human and non-human sera, cell and tissue homogenates or extracts.
3. A method according to claim 1 or claim 2, wherein said heparanase substrate is a labelled substrate.
4. A method according to claim 3, wherein said heparanase substrate is a radiolabelled substrate.
5. A method according to any of claims 1 to 4, wherein said heparanase substrate is a heparan sulphate.
6. A method according to claim 5, wherein said heparan sulphate is porcine mucosal heparan sulphate or bovine kidney heparan sulphate.

- 50 -

7. A method according to claim 6, wherein said heparan sulphate is ^3H porcine mucosal heparan sulphate or ^3H bovine kidney heparan sulphate.
8. A method according to any of claims 1 to 7, wherein said heparan sulphate-binding protein is a histidine-rich glycoprotein.
9. A method according to claim 8, wherein said histidine-rich glycoprotein is chicken histidine-rich glycoprotein.
10. A method according to any of claims 1 to 9, wherein said heparan sulphate-binding protein is immobilised.
11. A method according to claim 10, wherein said heparan sulphate-binding protein is immobilised by binding to agarose beads.
12. A method according to any of claims 1 to 11, wherein said sample is contacted with said heparanase substrate at a temperature in the range of 35°C to 40°C , preferably about 37°C , for a period of from 2 to 48 hours, preferably about 16 hours, at a pH in the range of from 4.2 to 7.5, preferably about pH 5.1.
13. A kit for use in the detection of mammalian heparanase activity in a sample, which comprises, in compartmentalised form:
 - i. heparanase substrate;
 - ii. heparan sulphate-binding protein; and
 - iii. optionally, directions for performing the method of the invention according to any of claims 1 to 12.
14. A kit according to claim 13, wherein said heparanase substrate is a labelled substrate.

- 51 -

15. A kit according to claim 14, wherein said heparanase substrate is a radiolabelled substrate.
16. A kit according to any of claims 13 to 15, wherein said heparanase substrate is a heparan sulphate.
17. A kit according to claim 16, wherein said heparan sulphate is porcine mucosal heparan sulphate or bovine kidney heparan sulphate.
18. A kit according to claim 17, wherein said heparan sulphate is ^3H porcine mucosal heparan sulphate or ^3H bovine kidney heparan sulphate.
19. A kit according to any of claims 13 to 18, wherein said heparan sulphate-binding protein is a histidine-rich glycoprotein.
20. A kit according to claim 19, wherein said histidine-rich glycoprotein is chicken histidine-rich glycoprotein.
21. A kit according to any of claims 13 to 20, wherein said heparan sulphate-binding protein is immobilised.
22. A kit according to claim 21, wherein said heparan sulphate-binding protein is immobilised by binding to agarose beads.
23. A method for the purification of mammalian heparanase from a heparanase-containing material, which comprises the steps of:
 - i. contacting the heparanase-containing material with an immobilised lectin affinity chromatography matrix in the presence of detergent to bind heparanase activity to said matrix;

- 52 -

- ii. eluting a first purified heparanase-containing fraction from said matrix;
 - iii. optionally contacting said first purified heparanase-containing fraction with an immobilised metal ion affinity chromatography matrix;
 - iv. contacting said first purified heparanase-containing fraction with a dye-resin matrix to bind heparanase activity to said dye-resin matrix; and
 - v. eluting a second purified heparanase-containing fraction from said dye-resin matrix.
24. A method according to claim 23, wherein said heparanase-containing material comprises human platelets.
25. A method according to claim 23 or claim 24, wherein said immobilised lectin affinity chromatography matrix comprises a concanavalin A-Sepharose matrix.
26. A method according to any of claims 23 to 25, wherein said detergent comprises Triton X-100.
27. A method according to any of claims 22 to 26, wherein said immobilised metal ion affinity chromatography matrix comprises a Zn^{2+} -chelating Sepha-rose matrix.
28. A method according to any of claims 22 to 27, wherein said dye resin matrix comprises a Blue A-resin or Reactive Red-resin matrix.
29. A method according to claim 28, wherein the resin in said dye-resin matrix comprises agarose, Sepharose or acrylamide.

- 53 -

30. A method according to any of claims 22 to 29, comprising the further step of contacting the second purified heparanase-containing fraction with an octyl-agarose matrix to remove contaminating proteins.
31. A method according to any of claims 23 to 30, comprising the further step of purification of said second purified heparanase-containing fraction or gel filtration chromatography.
32. A method according to claim 31, wherein said gel filtration chromatography comprises Superose 12 chromatography.
33. Substantially purified mammalian heparanase prepared by the method of any of claims 23 to 32.
34. Substantially purified human platelet heparanase characterised in that
 - i. it has a native molecular mass (M_r) of about 50kDa when analysed by gel filtration chromatography and by SDS-PAGE; and
 - ii. it degrades both heparin and heparan sulphates.
35. Substantially purified human platelet heparanase according to claim 34, characterised in that it degrades bovine lung and porcine mucosal heparin from 12kDa to 6 and 4kDa fragments respectively, and porcine mucosal heparan sulphate in a stepwise fashion from 22kDa to 5kDa fragments, by gel filtration analysis.




Figure 1

2/8




Figure 2

3/8




Figure 3

4/8




Figure 4

5/8




Figure 5

6/8




Figure 6




Figure 7

8/8




Figure 8

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00452

A. CLASSIFICATION OF SUBJECT MATTER												
Int Cl ⁶ : C12N 9/24												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) See Electronic Database Box below												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See Electronic Data base Box below												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPAT, Chem Abs, Medline Search Terms: Heparanase, Heparitinase, Heparan Sulphate Binding Protein												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	GRAHAM, L.D. and UNDERWOOD, P.A. Comparison of the Heparanase Enzymes from Mouse Melanoma Cells, Mouse Macrophages, and Human Platelets. <u>BIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL</u> , Vol. 39, No. 3, 1996, pages 563-571 See entire article.											
A	WO 91/19197 (Board of Regents, The University of Texas) 12 December 1991											
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier document but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 26 August 1997		Date of mailing of the international search report 29 AUG 1997										
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer J.H. CHAN Telephone No.: (02) 6283 2340										

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00452

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	<p>GILAT, D., et al</p> <p>"Molecular Behaviour Adapts to Context: Heparanase Functions as an Extracellular Matrix-degrading Enzyme or as a T Cell Adhesion Molecule, Depending on the local pH".</p> <p><u>Journal of Experimental Medicine</u></p> <p>Volume 181, May 1995, pages 1929-1034.</p> <p>see entire document</p>	34-35

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00452

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1-22: A method for the detection of mammalian heparanase and kit.
2. Claims 23-33: A method for the purification of mammalian heparanase
3. Claims 34-35: a purified human platelet heparanase.

None of these groups of claims are so linked by any novel technical feature as to be considered the same invention as any other group.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.